The coronavirus disease 2019 (COVID-19) pandemic is unlike anything seen before by modern science-based medicine. Health systems across the world are struggling to manage it. Added to this struggle are the effects of social confinement and isolation. This brings into question whether the latest guidelines are relevant in this crisis. We aim to support urologists in this difficult situation by providing tools that can facilitate decision making, and to minimise the impact and risks for both patients and health professionals delivering urological care, whenever possible. We hope that the revised recommendations will assist urologist surgeons across the globe to guide the management of urological conditions during the current COVID-19 pandemic.

A single instillation of chemotherapy immediately after resection reduces the risk of recurrence in non-muscle-invasive bladder cancer; however, it should not be given to patients at high risk of recurrence due to its lack of efficacy in this subgroup.

66Evidence acquisition: A systematic literature search was undertaken incorporating Medline, 67 Embase, and the Cochrane Library. Studies were critically appraised for risk of bias (QUIPS). 68For prognosis, the primary outcome was progression to muscle-invasive or metastatic 69 disease. Secondary outcomes were disease recurrence, overall and cancer-specific survival. 70For reproducibility, the primary outcome was inter-observer variability between 71 pathologists. Secondary outcome was intra-observer variability (repeatability) by the same 72 pathologist. Progression rates in G1 patients were similar to those in low grade patients; progression 77 rates in G3 patients were higher than in high grade patients. Survival data was limited.

No abstract